Malaria
Conditions
Interventions
Artemether Lumefantrine
Sponsors
Kenya Medical Research Institute
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: • age between 6 Months to 14 years • mono infection with P. falciparum confirmed by positive blood smear (i.e., no mixed infection). • parasitaemia of parasitaemia between 1,000 – 200,000 p/µl • presence of axillary or tympanic temperature = 37.5 °C or fever history during the past 24 h. • ability to swallow oral medication. • ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule. • informed consent from a parent or guardian and an informed assent from any minor participant aged from 12 to 14 years
Exclusion criteria
Exclusion criteria: • presence of general danger signs in children aged under 12 years or signs of severe falciparum malaria according to the definitions of WHO (Appendix 1) • weight under 5 kg. • haemoglobin 12 years and sexually active)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adequate clinical Parasitological Response | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Highlight the prevalence of Pfk13 antimalarial drug resistance marker. 2. Determine the use of the novel marker, Pfcoronin, as an indication for antimalarial drug resistance | — |
Countries
Kenya
Contacts
Public ContactElijah Songok
Director General Kenya Medical Research Institute
Outcome results
None listed